scholarly journals French-American-British Classification

2020 ◽  
Author(s):  
Keyword(s):  
French American British

Krampfanfälle bei einem Hund mit akuter myeloblastischer Leukämie

2004 ◽  
Vol 32 (01) ◽  
pp. 15-20
Author(s):  
I. Kathmann ◽  
D. Ledieu ◽  
K. Allenspach ◽  
G. Fodor ◽  
A. Jaggy ◽  
...  
Keyword(s):  
Akute Leukämien ◽  
French American British

Zusammenfassung:Als Leukämie bezeichnet man eine neoplastische Wucherung von hämatopoetischen Vorläuferzellen im Knochenmark. Entsprechend der FAB-(French-American-British-) Klassifizierung beim Menschen können auch Leukämien beim Tier durch die normale Zytologie und Resultate immunhistochemischer und zytoenzymatischer Untersuchungen in weitere Gruppen unterteilt werden. Akute Leukämien kommen beim Hund selten vor. Das Auftreten von Krampfanfällen im Zusammenhang mit einer akuten myeloiden Leukämie beim Hund wurde unseres Wissens noch nie beschrieben. Es wird ein Literaturüberblick gegeben und der Fall einer vierjährigen Dalmatiner-Mischlingshündin beschrieben, die wegen epileptischer Krampfanfälle, Schwächezuständen und Inkoordination überwiesen wurde. Unter Berücksichtigung der zytologischen, zytoenzymatischen und immunhistochemischen Resultate handelte es sich um eine akute myeloblastische Leukämie (AML1 oder AML5).

A new case of acute nonlymphocytic leukemia (French–American–British subtype M1) with double minutes and c-MYC amplification

2002 ◽  
Vol 132 (2) ◽  
pp. 161-164 ◽  
Author(s):  
Natàlia Rodon ◽  
Francesc Solé ◽  
Blanca Espinet ◽  
Marta Salido ◽  
Lourdes Zamora ◽  
...  
Keyword(s):  
Acute Nonlymphocytic Leukemia ◽  
Double Minutes ◽  
French American British

Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype

Blood ◽  
2005 ◽  
Vol 106 (4) ◽  
pp. 1419-1422 ◽  
Author(s):  
Giovanni Cazzaniga ◽  
Maria Grazia Dell'Oro ◽  
Cristina Mecucci ◽  
Emanuela Giarin ◽  
Riccardo Masetti ◽  
...  
Keyword(s):  
Residual Disease ◽  
Normal Karyotype ◽  
Myelogenous Leukemia ◽  
Potential Candidate ◽  
Npm1 Mutation ◽  
Reading Frame ◽  
Targeted Treatments ◽  
Acute Myelogenous ◽  
Childhood Aml ◽  
French American British

AbstractNucleophosmin (NPM) is a nucleocytoplasmic shuttling protein involved in leukemia-associated chromosomal translocations, and it regulates the alternate reading frame (ARF)-p53 tumorsuppressor pathway. Recently, it has been demonstrated that mutations of the NPM1 gene alter the protein at its C-terminal, causing its cytoplasmic localization. Cytoplasmic NPM was detected in 35% of adult patients with primary non-French-American-British (FAB) classification M3 acute myeloid leukemia (AML), associated mainly with normal karyotype. We evaluated the prevalence of the NPM1 gene mutation in non-M3 childhood AML patients enrolled in the ongoing Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP-AML02) protocol in Italy. NPM1 mutations were found in 7 (6.5%) of 107 successfully analyzed patients. NPM1- mutated patients carried a normal karyotype (7/26, 27.1%) and were older in age. Thus, the NPM1 mutation is a frequent abnormality in AML patients without known genetic marker; the mutation may represent a new target to monitor minimal residual disease in AML and a potential candidate for alternative and targeted treatments. (Blood. 2005;106:1419-1422)

Clinical Features of DIC According to the French-american-british (FAB) Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatment – Cross-sectional Analysis of a Post-marketing Surveillance Study Cohort –

2021 ◽  
Author(s):  
Yoshinobu Seki ◽  
Goichi Honda ◽  
Noriaki Kawano ◽  
Toshimasa Uchiyama ◽  
Kazuo Kawasugi ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Clinical Features ◽  
Lymphoblastic Leukemia ◽  
Study Cohort ◽  
Cross Sectional ◽  
Safety And Efficacy ◽  
Post Marketing Surveillance ◽  
Fab Classification ◽  
Post Marketing ◽  
French American British

Abstract Background: The aims of this study were to analyze the clinical features of a large number of cases with disseminated intravascular coagulation (DIC) associated with acute leukemia, and to clarify the safety and efficacy of thrombomodulin alfa (TM-α) using the French-American-British (FAB) classification of hematological malignancies.Methods: We retrospectively examined 644 patients with acute leukemia in post-marketing surveillance for TM-α.Results: M3, M2, M4, M1, and M5 subtypes of acute myeloid leukemia (AML), and L2 and L1 subtypes of acute lymphoblastic leukemia (ALL) have been found more frequently among patients with DIC. Bleeding symptoms at baseline were more frequent in M3 and M7 subtypes. Fibrinogen concentrations were lower and plasmin-plasmin inhibitor complex values were higher in M3 and Philadelphia-positive (Ph+) ALL. Overall DIC resolution rate was 60.2% with higher rates in L1 and Ph+ ALL, lower in M1, and generally higher in ALL than in AML. The overall survival rate was 79.8%, generally high, with higher survival rates in L3, Ph+ ALL, and M3. In M3 and M7, with high frequencies of pre-existing bleeding, TM-α improved bleeding symptoms. Post-administration DIC scores in each subtype were significantly improved compared with pre-administration scores, except in M6, M7, and MDS-overt AML.Conclusions: This study showed the clinical features of DIC associated with acute leukemia among FAB classifications and also elucidated the safety and efficacy profiles of TM-α by detailed classification based on the FAB classification in clinical practice.Trial registration: The clinical characteristics and treatment outcomes of patients with DIC treated with TM-α between May 2008 and April 2010 were retrospectively analyzed by subgroup analysis of post-marketing surveillance data.

scholarly journals Expression of the c-mpl proto-oncogene in human hematologic malignancies

Blood ◽  
1993 ◽  
Vol 82 (3) ◽  
pp. 877-883 ◽  
Author(s):  
I Vigon ◽  
F Dreyfus ◽  
J Melle ◽  
F Viguie ◽  
V Ribrag ◽  
...  
Keyword(s):  
Northern Blot Analysis ◽  
Bone Marrow Cells ◽  
Myeloproliferative Disorders ◽  
Hematologic Malignancies ◽  
Lymphoid Malignancies ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
French American British ◽  
Stimulating Factor

Abstract Similar to two other hematopoietic growth factor receptors, the c-fms (macrophage colony-stimulating factor receptor) and the c-kit genes, c- mpl has been discovered through the study of oncogenic retroviruses. Unlike c-fms and c-kit, which both belong to a subgroup of tyrosine kinase receptors, the c-mpl proto-oncogene encodes a new member of the cytokine receptor superfamily. We have studied the expression of c-mpl in a series of 105 patients with hematologic malignancies using Northern blot analysis. The levels of c-mpl transcripts in lymphoid malignancies and in chronic myeloproliferative disorders were not significantly different from those found in normal bone marrow cells, in which c-mpl was barely detectable. In contrast, c-mpl expression was increased in 26 of 51 patients with acute myeloblastic leukemia (AML) and in 5 of 16 patients with myelodysplastic syndromes. Amplification of the c-mpl gene was detected in genomic DNA of one M4 AML patient. There was no significant correlation between c-mpl expression and the French-American-British classification of AML. Patients with high c-mpl expression appeared to belong to a subgroup of AML with a low rate of complete remission and a poor prognosis, including secondary leukemia and AML with unfavorable cytogenetic abnormalities.

scholarly journals Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia

Blood ◽  
1992 ◽  
Vol 80 (11) ◽  
pp. 2873-2882 ◽  
Author(s):  
OI Olopade ◽  
M Thangavelu ◽  
RA Larson ◽  
R Mick ◽  
A Kowal-Vern ◽  
...  
Keyword(s):  
Myeloid Leukemia ◽  
De Novo ◽  
Chromosomal Abnormalities ◽  
Normal Karyotype ◽  
Intensive Chemotherapy ◽  
Trisomy 8 ◽  
Cytogenetic Abnormalities ◽  
Favorable Prognosis ◽  
Multiple Abnormalities ◽  
French American British

Abstract We have performed a retrospective analysis of the clinical, morphologic, and cytogenetic findings in 26 patients diagnosed between January 1969 and September 1991 with acute erythroblastic leukemia de novo (EL or AML-M6). Clonal chromosomal abnormalities were found in 20 (77%) patients (95% confidence interval [CI], 61% to 93%). Loss of all or part of the long arm (q) of chromosomes 5 and/or 7 was observed in 17 (65%) patients (95% CI, 47% to 83%). In addition, the karyotypes were often complex, with multiple abnormalities and subclones. Among the remaining nine patients, six had a normal karyotype and one each had trisomy 8, t(3;3), or t(3;5). The overall frequency of abnormalities of chromosomes 5 and/or 7 observed in our M6 patients is similar to that observed in our patients with therapy-related acute myeloid leukemia (t-AML; 99 of 129 patients, 77%), but substantially higher than that noted in our other patients with AML de novo (French- American-British [FAB] subtypes M1-M5: 52 of 334 patients, 16%). Our M6 patients with abnormalities of chromosomes 5 and/or 7 were older and had a shorter median survival (16 v 77 weeks [P = .005]) than did the M6 patients without these abnormalities. We found no correlation between morphologic features and either cytogenetic abnormalities or clinical outcome. Of note was the finding that the percentage of myeloblasts, which may account for only a small fraction of the total marrow elements when the revised FAB criteria are applied, had no bearing on prognosis. We conclude that acute erythroblastic leukemia, when defined by morphologic criteria, consists of two distinctive subgroups: one group tends to be older, has complex cytogenetic abnormalities, especially of chromosomes 5 and/or 7, and shares biologic and clinical features with t-AML; the other group, with simple or no detectable cytogenetic abnormalities, has a more favorable prognosis when treated with intensive chemotherapy.

O-7 Difference in clinical featuresbetween Japanese and German patients with refractory anemia according to the French-American-British classification

2005 ◽  
Vol 29 ◽  
pp. S2-S3
Author(s):  
A. Matsuda ◽  
U. Germing ◽  
I. Jinnai ◽  
M. Misumi ◽  
A. Kuendgen ◽  
...  
Keyword(s):  
Refractory Anemia ◽  
French American British

scholarly journals Simultaneous or sequential expression of lymphoid and myeloid phenotypes in acute leukemia

Blood ◽  
1985 ◽  
Vol 65 (1) ◽  
pp. 142-148 ◽  
Author(s):  
PB Neame ◽  
P Soamboonsrup ◽  
G Browman ◽  
RD Barr ◽  
N Saeed ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Myeloid Leukemia ◽  
Chromosomal Abnormalities ◽  
Lymphoblastic Leukemia ◽  
Differentiation Markers ◽  
Lymphoid Leukemia ◽  
Chromosome Marker ◽  
Fab Classification ◽  
Blast Cells ◽  
French American British

Abstract Acute mixed myeloid-lymphoid leukemia is uncommon. We report four cases in which myeloid and lymphoid cell markers were observed simultaneously or sequentially when 94 patients with acute leukemia were phenotyped according to the French-American-British (FAB) classification system, with cytochemical stains, and with immunologically defined differentiation markers (identified by monoclonal antibodies and antiterminal deoxynucleotidyl transferase [TdT]). In one case, conversion from acute lymphoblastic leukemia to acute myeloid leukemia was noted (FAB L1, TdT+ to FAB M4, Auer rods, TdT-). In another patient, two distinct populations of myeloid and lymphoid blast cells were observed simultaneously (TdT-, LeuM1+/TdT+, LeuM1-). In two additional patients, acute leukemia was characterized by the expression of both lymphoid and myeloid markers on the same cell (TdT+/Leu M1+, B4+/Leu M1+ and greater than or equal to 70% TdT+, T11+, My9+). The Philadelphia (Ph1) chromosome was negative in all cases, though other chromosomal abnormalities were noted in three out of four cases. Malignant transformation of a pluripotential stem cell for both lymphoid and myeloid lineages, with or without the Ph1 chromosome marker, could explain the coexistence of distinct populations of lymphoblasts and myeloblasts in acute leukemia. Acute leukemia with a biphenotypic profile may reflect genome depression accompanying neoplasia.

Sign in / Sign up

Export Citation Format

Share Document